Nrx pharmaceuticals, inc. (nasdaq: nrxp) announces fda qualified infectious disease product (qidp) and fast track designation of nrx-101 in complicated urinary tract infection and pyelonephritis

Nrx-101 has demonstrated potent activity against resistant urinary pathogens upon fda review qidp designation grants priority review and an additional 5 years of additional product exclusivity 3 million americans develop complicated urinary tract infection (cuti) each year at a cost that ranges from $4497 to $17,431 with a high rate of antibiotic resistance and need for inpatient hospitalization1 unlike many advanced-generation antibiotics, nrx-101 is not contra-indicated in sulfa and penicillin allergic patients and is not believed to disrupt the normal intestinal microbiome, potentially leading to reduced risk of c. difficile infection data have been accepted for posting on biorxiv and are under review at a peer-reviewed journal3 radnor, pa.
NRXP Ratings Summary
NRXP Quant Ranking